Información del artículo
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn. GETECCU 2001. Gastroenterol Hepatol. 2002; 25:162-9.
[2]
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345:1098-104.
[3]
Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol. 2003; 26:29-33.
[4]
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50:372-9.
[5]
Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol. 2001; 96:1665-6.
[6]
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter activesurveillance report. Arthritis Rheum. 2003; 48:2122-7.
[7]
Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine. 2002; 69:170-2.
[8]
Guidelines for using the Quantiferon®-TB test for diagnosing latent Mycobacterium tuberculosis Infection. MMWR Morb Mort tal Wkly Rep. 2003; 52:15-8. (RR02)
[9]
Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003; 361:1168-73.
[10]
Latent tuberculosis infection. N Engl J Med. 2002; 347:1860-6.
[11]
Infección tuberculosa latente en población indigente. Comparación de dos pautas terapéuticas. Med Clin (Barc). 2004; 122:57-9.
[12]
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002; 137:640-7.
[13]
Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003; 29:2327-9.
[14]
Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol. 2003; 30:1657-8.
[15]
Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology (Oxford). 2003; 42:901-2.
[16]
Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005; 40:756-9.
[17]
Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med. 2005; 99:648-52.
[18]
Treatment of latent tuberculosis infection. N Engl J Med. 2003; 348:1292-3.
[19]
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541-9.
[20]
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350:876-85.
